Finsbury Park mum saved by cancer drug disgusted at David Cameron’s plans to cut crucial medicine
PUBLISHED: 06:30 22 January 2015 | UPDATED: 16:45 23 January 2015
A mother who made a miraculous recovery from leukaemia has pleaded with David Cameron not to cut the drug that has given her three more years with her daughter.
Eli Beaumont, of Finsbury Park, was diagnosed with a rare and aggressive form of acute myeloid leukaemia in April 2012 when her daughter Otty was just nine months old.
But thanks to intensive chemotherapy and total body irradiation she was able to receive a stem cell transplant from one of her sisters who was fortunately a perfect match.
But the nature of her cancer means Mrs Beaumont has to take a drug called Dasatinib to stop it from coming back, a drug which is one of 25 set to be de-listed under plans announced by the Government last week.
“When I was first diagnosed my daughter was only nine months old – now she’s three,” said Mrs Beaumont, 44.
“I’ve seen three birthdays I never thought I would see.
“Without this drug, there is no guarantee she would have any memory of me.
“When I read about the plans to de-list a number of life-extending cancer drugs I was utterly disgusted.
“This funding decision is heartbreaking for patients and their families, already shattered by a cancer diagnosis, and I cannot understand how it can possibly be justified.”
As she was prescribed the drug before April this year Mrs Beaumont will still be able to receive Dasatinib.
But from April Dasatinib and other life-prolonging drugs taken by thousands of patients for breast and bowel cancer will no longer be funded by the Cancer Drug Fund (CDF).
Mrs Beaumont has set up a petition to try to stop this from happening.
“These drugs can give a person anywhere between two months and up to a year or more with the people they love,” she said.
“I think it’s unforgivable because we’re not a poor country, we’re a rich country with huge inequality and unfair distribution of money.”
Professor Peter Clark, chairman of the CDF and a practising oncologist, said: “We have been through a robust, evidence-based process to ensure the drugs available offer the best clinical benefit, getting the most for patients from every pound. There were drugs that did not offer sufficient clinical benefit so we simply cannot go on funding those.”
Mrs Beaumont’s petition, already signed by more than 1,000 people, can be found here.